Inventor
ALVARO GIUSEPPE
GB60 patents
⚠️ This page may combine multiple inventors who share the name “ALVARO GIUSEPPE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AUTIFONY THERAPEUTICS LTD
18 patentsUS10098881B2Oct 16, 2018
Compounds
AUTIFONY THERAPEUTICS LTD8 citations92
US9833452B2Dec 5, 2017
Compounds
AUTIFONY THERAPEUTICS LTD7 citations92
US9422272B2Aug 23, 2016
Compounds
AUTIFONY THERAPEUTICS LTD11 citations92
US9133175B2Sep 15, 2015
Compounds
AUTIFONY THERAPEUTICS LTD18 citations92
US10835534B2Nov 17, 2020
Compounds
AUTIFONY THERAPEUTICS LTD3 citations84
US10555945B2Feb 11, 2020
Compounds
AUTIFONY THERAPEUTICS LTD3 citations84
US9849131B2Dec 26, 2017
Imidazolidinedione derivatives
AUTIFONY THERAPEUTICS LTD4 citations83
US9216967B2Dec 22, 2015
Imidazolidinedione derivatives
AUTIFONY THERAPEUTICS LTD5 citations83
US9422252B2Aug 23, 2016
Triazoles as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD5 citations82
US11944623B2Apr 2, 2024
Modulators of Kv3 channels to treat pain
AUTIFONY THERAPEUTICS LTD2 citations72
US11147813B2Oct 19, 2021
Modulators of KV3 channels to treat pain
AUTIFONY THERAPEUTICS LTD2 citations72
US10058551B2Aug 28, 2018
Imidazolidinedione derivatives
AUTIFONY THERAPEUTICS LTD3 citations72
US11197859B2Dec 14, 2021
Hydantoin derivatives useful as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD1 citations71
US10265316B2Apr 23, 2019
Hydantoin derivatives useful as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD1 citations71
US12358901B2Jul 15, 2025
KV3 modulators
AUTIFONY THERAPEUTICS LTD0 citations62
US11541052B2Jan 3, 2023
Compounds
AUTIFONY THERAPEUTICS LTD0 citations62
US11583527B2Feb 21, 2023
Hydantoin derivatives useful as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD0 citations61
US11180461B2Nov 23, 2021
Triazoles as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD0 citations61
ALVARO GIUSEPPE
11 patentsUS9346790B2May 24, 2016
Hydantoin derivatives useful as Kv3 inhibitors
ALVARO GIUSEPPE16 citations91
US8153681B2Apr 10, 2012
Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide
ALVARO GIUSEPPE9 citations83
US8143306B2Mar 27, 2012
Methods of treating bipolar disorders
ALVARO GIUSEPPE8 citations83
US8129384B2Mar 6, 2012
Imidazo[1,2-a]pyrazines as orexin receptor antagonists
ALVARO GIUSEPPE7 citations83
US8093268B2Jan 10, 2012
Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
ALVARO GIUSEPPE12 citations83
US8093255B2Jan 10, 2012
Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
ALVARO GIUSEPPE8 citations83
US8722695B2May 13, 2014
Imidazolidinedione derivatives
ALVARO GIUSEPPE9 citations82
US8153623B2Apr 10, 2012
Compounds
ALVARO GIUSEPPE9 citations81
US8133908B2Mar 13, 2012
Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine
ALVARO GIUSEPPE10 citations79
US9193704B2Nov 24, 2015
Hydantoin derivatives as KV3 inhibitors
ALVARO GIUSEPPE6 citations72
US8097618B2Jan 17, 2012
Pyridine derivatives and their use in the treatment of psychotic disorders
ALVARO GIUSEPPE3 citations62
GLAXO GROUP LTD
6 patentsUS7655693B2Feb 2, 2010
Compounds
GLAXO GROUP LTD14 citations92
US7803833B2Sep 28, 2010
Compounds
GLAXO GROUP LTD10 citations81
US7652012B2Jan 26, 2010
2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide maleate and pharmaceutical compositions thereof
GLAXO GROUP LTD2 citations60
US7189713B2Mar 13, 2007
Piperidine derivatives
GLAXO GROUP LTD2 citations60
US7534893B2May 19, 2009
Imidazol-2-one compounds useful in the treatment of various disorders
GLAXO GROUP LTD5 citations54
US7276509B2Oct 2, 2007
Piperidine derivatives and their use as antagonists of tachykinins
GLAXO GROUP LTD1 citations52
SMITHKLINE BEECHAM CORP
6 patentsUS6642240B2Nov 4, 2003
Treating emesis in a mammal
SMITHKLINE BEECHAM CORP31 citations92
US7294630B2Nov 13, 2007
Piperazinyl piperidine tachykinin antagonists
SMITHKLINE BEECHAM CORP6 citations74
US7345041B2Mar 18, 2008
Chemical compounds
SMITHKLINE BEECHAM CORP2 citations62
USRE39921ENov 13, 2007
Chemical compounds
SMITHKLINE BEECHAM CORP3 citations60
US7119092B2Oct 10, 2006
Chemical compounds
SMITHKLINE BEECHAM CORP3 citations60
US7060702B2Jun 13, 2006
Chemical compounds
SMITHKLINE BEECHAM CORP3 citations60
GLAXOSMITHKLINE LLC
3 patentsUS7683056B2Mar 23, 2010
Pyridine derivatives and their use in the treatment of psychotic disorders
GLAXOSMITHKLINE LLC19 citations92
US7919491B2Apr 5, 2011
Pyridine derivatives and their use in the treatment of psychotic disorders
GLAXOSMITHKLINE LLC4 citations74
US7648990B2Jan 19, 2010
Chemical compounds
GLAXOSMITHKLINE LLC1 citations54
NERRE THERAPEUTICS LTD
2 patentsUS9006271B2Apr 14, 2015
5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists
NERRE THERAPEUTICS LTD0 citations51
US8822504B2Sep 2, 2014
5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists
NERRE THERAPEUTICS LTD0 citations51
SMITHKLINE BEECHAN CORP
1 patentCONVERGENCE PHARMACEUTICALS
1 patentGLAXO WELLCOME MFG PTE LTD
1 patentSMITHKLINE BEECHAM CROP
1 patentShowing the top 50 of 60 patents by PatentIndex Score.